Conditions: Non-Hodgkin's Lymphoma
Keywords: non-Hodgkin's lymphoma autologous stem cell transplantation radioimmunotherapy zevalin
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 60
Healthy volunteers: no

Brief summary:
The study hypothesis is that the addition of zevalin radioimmunotherapy to the conditioning regimen given prior to BEAM high-dose chemotherapy and autologous stem cell transplantation in patients with aggressive lymphoma will reduced disease recurrence rate and improve overall and disease-free survival.

Detailed description:

Arms:
arm 1: ibritumomab tiuxetan (zevalin) BEAM arm 2: standard BEAM chemotherapy

Interventions: intervention 1: ibritumomab tiuxetan intervention 2: BEAM chemotherapy and autologous stem-cell transplantation
Intervention descriptions: intervention 1: 0.4 mCi/kg intervention 2: None

Protocol document: